Introduction Executive Summary Glioblastoma: Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Glioblastoma – DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Glioblastoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends Glioblastoma Collaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) ● Comparative Analysis Enzastaurin Hydrochloride: Denovo Biopharma ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) ● Comparative Analysis ONC-201: Oncotherapeutics ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I/II) ● Comparative Analysis CC-90010: Celgene Corporation ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Preclinical Stage Products ● Comparative Analysis MT-201: Myeloid Therapeutics ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Glioblastoma Key Companies Glioblastoma Key Products Glioblastoma- Unmet Needs Glioblastoma- Market Drivers and Barriers Glioblastoma- Future Perspectives and Conclusion Glioblastoma Analyst Views Glioblastoma Key Companies Appendix

Table 1 Total Products for Glioblastoma Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Celgene Corporation • Oncoceutics, Inc. • MediciNova • Genenta Sceince • Philogen S.p.A. • VBI Vaccines Inc. • Apollomics Inc. • InSightec • Karyopharm Therapeutics Inc • Vaximm GmbH • OX2 Therapeutics • Laminar Pharmaceuticals • Ziopharm • Arcus Biosciences, Inc. • Novartis Pharmaceuticals • NovoCure Ltd. • Denovo Bipharma LLC • NuvOx LLC • Imvax • PharmAbcine • Eli Lilly and Company • I-Mab Biopharma Co. Ltd. • CNS pharmaceuticals • Aivita Biomedical, Inc. • Immunitor LLC • Oblato, Inc. • Kintara Therapeutics, Inc. • Jiangsu HengRui Medicine Co., Ltd. • CANbridge Life Sciences Ltd. • Myeloid Theraputics • Innovio Pharmaceuticals • Regeneron Pharmaceuticals • Ocuphire Pharma • Peregrine Pharmaceuticals • Celldex Therapeutics